FOLD Key Stats
- AMICUS THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of S... Jun 18
- Stocks Pare Gains on Speculation of Fed Tapering Jun 17
- Amicus Therapeutics' CEO Presents at Fabry Monotherapy Strategic Update Conferen... Jun 17
- Notable 52-Week Highs and Lows of the Day 06/17: (MU) (CSCO) (ALU) High; (WLT) (... Jun 17
- Unusual 11 Mid-Day Movers 06/17: (KNDI) (FRO) (LIVE) Higher; (FOLD) (ORMP) (SGOC... Jun 17
- Analysts: Yahoo Won’t Reach Google Deal and 3 More Research Notes to Explore Jun 17
- Amicus Falls as Fabry Disease Drug Trials Need More Time Jun 17
- Amicus falls to annual low on Fabry drug ruling Jun 17
- Tesla Rides a New Upgrade, BioScrip Buys CarePoint, and 3 More Hot Stocks Jun 17
- StreetInsider.com Pre-Open Movers 6/17: (KNDI) (NFLX) (AMD) Higher; (FOLD) (TEX)... Jun 17
FOLD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Amicus Therapeutics is down 52.42% over the last year vs S&P 500 Total Return up 23.89%, Achillion Pharmaceuticals up 23.63%, and Insmed up 273.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for FOLD
Pro Report PDF for FOLD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download FOLD Pro Report PDF
Pro Strategies Featuring FOLD
Did Amicus Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.